NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Livia Lontai  ¹     Lorant Gonczi  ¹     Fruzsina Balogh  ¹     Nora Komlodi  ¹     Tamás Resál  ²     Klaudia Farkas  ²     Tamás Molnár  ²     Pal Miheller  ²     Petra Anna Golovics  ³     Eszter Schäfer  ³     Tamás Szamosi  ³     Ákos Iliás  ³     Peter L Lakatos  ^4    
1 Semmelweis University, Budapest, Hungary
² University of Szeged, Szeged, Hungary
³ Hungarian Defence Forces Medical Centre, Budapest, Hungary
⁴ McGill University Health Center, Montreal, Canada

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)